Study identifier:NIS-CTH-DUM-2007/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Lipid-lowering therapy in patients with high cardiovascular risk and their 3-year mortality rate in general practice in Thailand
Dyslipidemia
-
No
-
All
1240
Observational
20 Years - 80 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The first phase of the study is a hospital-based cross-sectional, epidemiological survey. The required sample size is 1,260 patients from 50 hospitals across Thailand. Each of the hospital will enroll 10 to 40 consecutive patients, depending on case availability on the date conducting the survey, with dyslipidemia and classified as high risk as defined by the protocol. Lipid levels will be based on serological analysis conducted by a local laboratory. For the second phase, each subject will be followed for survival status at 36 months after enrollment. Such follow-up will be done by searching the Thai National Vital Event Registration Database using subjects' Population Identification Number. All activities regarding case selection and data collection will be done by well trained clinical research associates (CRAs). The CRAs are from Khon Kaen University where the Statistical Coordinating Center (SCC) for this project is based and are independent of the investigator. Random auditing visits will also be performed by auditors independent of the SCC. These are to ensure not only high quality data but also protecting right and well being of subjects.
Location
Location
Maung, Ang Thong, Thailand
Location
Maung, Ayutthaya, Thailand
Location
Kannayao, Bangkok, Thailand
Location
Maung, Chachoengsao, Thailand
Location
Maung, Chainat, Thailand
Location
Maung, Chantaburi, Thailand
Location
Maung, Chiang Mai, Thailand
Location
Maung, Chumphon, Thailand
Arms | Assigned Interventions |
---|---|
1 Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.